Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rudi W Hendriks

Showing results (21-30 of 196) with videos related to

Pageof 20
Sort By:
Cells|November 11, 2022
Aberrant B Cell Signaling in Autoimmune DiseasesOdilia B J Corneth, Stefan F H Neys, Rudi W Hendriks
Frontiers in Cell and Developmental Biology|June 21, 2021
Targeting Bruton's Tyrosine Kinase in Inflammatory and Autoimmune PathologiesStefan F H Neys, Rudi W Hendriks, Odilia B J Corneth
Current Pharmaceutical Design|May 18, 2012
The role of B cell receptor stimulation in CLL pathogenesisLaurens P Kil, Saravanan Yuvaraj, Anton W Langerak, et al.
Expert Opinion on Therapeutic Targets|June 4, 2011
Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in manRudi W Hendriks, Robbert Gm Bredius, Karin Pike-Overzet, et al.
Current Cancer Drug Targets|April 9, 2016
Targeting Signaling Pathways in Chronic Lymphocytic LeukemiaAlice F Muggen, Simar P Singh, Rudi W Hendriks, et al.
Immunity|September 18, 2007
Surrogate-light-chain silencing is not critical for the limitation of pre-B cell expansion but is for the termination of constitutive signalingPieter Fokko van Loo, Gemma M Dingjan, Alex Maas, et al.
Current Topics in Microbiology and Immunology|September 6, 2015
BTK Signaling in B Cell Differentiation and AutoimmunityOdilia B J Corneth, Roel G J Klein Wolterink, Rudi W Hendriks
Immunological Reviews|February 28, 2025
Chronic Inflammation in Asthma: Looking Beyond the Th2 CellSimone E M Olsthoorn, Anneloes van Krimpen, Rudi W Hendriks, et al.
Blood|April 28, 2012
DNA-binding factor CTCF and long-range gene interactions in V(D)J recombination and oncogene activationClaudia Ribeiro de Almeida, Ralph Stadhouders, Supat Thongjuea, et al.
Drugs|October 5, 2021
Bruton's Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune DiseaseStefan F H Neys, Jasper Rip, Rudi W Hendriks, et al.
Pageof 20

Showing results (21-30 of 196) with videos related to

Sort By:
Pageof 20
Cells|November 11, 2022
Aberrant B Cell Signaling in Autoimmune DiseasesOdilia B J Corneth, Stefan F H Neys, Rudi W Hendriks
Frontiers in Cell and Developmental Biology|June 21, 2021
Targeting Bruton's Tyrosine Kinase in Inflammatory and Autoimmune PathologiesStefan F H Neys, Rudi W Hendriks, Odilia B J Corneth
Current Pharmaceutical Design|May 18, 2012
The role of B cell receptor stimulation in CLL pathogenesisLaurens P Kil, Saravanan Yuvaraj, Anton W Langerak, et al.
Expert Opinion on Therapeutic Targets|June 4, 2011
Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in manRudi W Hendriks, Robbert Gm Bredius, Karin Pike-Overzet, et al.
Current Cancer Drug Targets|April 9, 2016
Targeting Signaling Pathways in Chronic Lymphocytic LeukemiaAlice F Muggen, Simar P Singh, Rudi W Hendriks, et al.
Immunity|September 18, 2007
Surrogate-light-chain silencing is not critical for the limitation of pre-B cell expansion but is for the termination of constitutive signalingPieter Fokko van Loo, Gemma M Dingjan, Alex Maas, et al.
Current Topics in Microbiology and Immunology|September 6, 2015
BTK Signaling in B Cell Differentiation and AutoimmunityOdilia B J Corneth, Roel G J Klein Wolterink, Rudi W Hendriks
Immunological Reviews|February 28, 2025
Chronic Inflammation in Asthma: Looking Beyond the Th2 CellSimone E M Olsthoorn, Anneloes van Krimpen, Rudi W Hendriks, et al.
Blood|April 28, 2012
DNA-binding factor CTCF and long-range gene interactions in V(D)J recombination and oncogene activationClaudia Ribeiro de Almeida, Ralph Stadhouders, Supat Thongjuea, et al.
Drugs|October 5, 2021
Bruton's Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune DiseaseStefan F H Neys, Jasper Rip, Rudi W Hendriks, et al.
Pageof 20